NGM BIOPHARMACEUTICALS INC (NGM)
US62921N1054 - Common Stock
NGM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for NGM as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, NGM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
NGM had negative earnings in the past year.
In the past year NGM has reported a negative cash flow from operations.
NGM had negative earnings in each of the past 5 years.
NGM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -84.31%, NGM is not doing good in the industry: 74.87% of the companies in the same industry are doing better.
NGM has a Return On Equity (-95.79%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.31% | ||
| ROE | -95.79% | ||
| ROIC | N/A |
ROA(3y)-55.71%
ROA(5y)-41.91%
ROE(3y)-64.77%
ROE(5y)-48.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NGM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NGM has been increased compared to 1 year ago.
NGM has more shares outstanding than it did 5 years ago.
NGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NGM has an Altman-Z score of -4.16. This is a bad value and indicates that NGM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.16, NGM is not doing good in the industry: 61.81% of the companies in the same industry are doing better.
NGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.16 |
ROIC/WACCN/A
WACC9.2%
2.3 Liquidity
NGM has a Current Ratio of 7.79. This indicates that NGM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NGM (7.79) is better than 79.90% of its industry peers.
A Quick Ratio of 7.79 indicates that NGM has no problem at all paying its short term obligations.
NGM has a Quick ratio of 7.79. This is amongst the best in the industry. NGM outperforms 80.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.10% over the past year.
NGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.02%.
NGM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -47.30% yearly.
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q26.67%
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y-47.3%
Revenue growth Q2Q-99.09%
3.2 Future
NGM is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.98% yearly.
The Revenue is expected to grow by 69.25% on average over the next years. This is a very strong growth
EPS Next Y29.44%
EPS Next 2Y20.23%
EPS Next 3Y11.9%
EPS Next 5Y6.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y94.76%
Revenue Next 5Y69.25%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NGM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.23%
EPS Next 3Y11.9%
5. Dividend
5.1 Amount
No dividends for NGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NGM BIOPHARMACEUTICALS INC
NASDAQ:NGM (4/4/2024, 7:17:51 PM)
After market: 1.55 +0.01 (+0.65%)1.54
-0.02 (-1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap128.53M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.31% | ||
| ROE | -95.79% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y29.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y